The dial-in number is 888-679-8034 for domestic callers and 617-213-4847 for international callers. Par's reported, or GAAP, chemist loss from continuing trapezius pain treatment skin care with retinol succinate to new customers. This is compared with reported revenues of $769.7 million and income from continuing operations prescription medication of $51.1 million, or $1.47 per diluted share, for 2007.
Adjusting for these items, income from continuing operations for the fourth quarter of 2007 would have been $6.5 million, or $0.19 per diluted share. Adjusting for these items and the fourth quarter special items, income from continuing operations for the full year ended would have been $1.8 million, or $0.05 per diluted share. This is compared with reported net income of $4.3 pain killers million, or $0.12 per share, for the same period in 2007.
Generic product gross margin decreased to 22.2% of generic revenues in 2008 from 29.8% of generic revenues in 2007 driven by increased sales of lower margin metoprolol succinate, lower sales of existing products as mentioned above, and an impairment charge cipralex side effects tamoxifen of $4.9 million for nabumetone, and lower inventory write-offs, in addition to the other factors discussed above. Par has scheduled a conference call for at 9:00 am EST to discuss results for the fourth quarter and full year 2008. Par reported pain medication a loss for the fourth quarter ended of $32.0 million, viagra side effects or $0.96 per share. Revenues from Par's generic segment declined 28.3% for the full year 2008 to $491.1 million primarily due to competitive pressures that adversely affected the volume and pricing of certain existing products.
A replay of the conference call will be pain medication available commencing approximately one hour after the call. Com stock and $4.6 million of additional share-based compensation advair effects on body building expense related to Par's employee stock option tender offer. The $15.4 million fourth quarter charge related to the restructuring will result in cash expenditures of approximately $6.0 million in 2009. Adjusting for these items, prescription medication costs pain meds income from continuing operations for the full year ended would have been $55.1 million, or $1.59 per diluted share. Develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. cipralex how can i control weight gain Par Pharmaceutical Companies, Inc. Generic RD expense decreased $8.0 million due to lower internal development costs, lower performance incentive compensation online pharmacies of $4 million, and the non-recurrence of one-time costs associated with a third party development agreement.
On-going RD expense in support of Par's strategy to expand Strativa increased $1.7 million driven by costs related to the development of Zensana(TM). This is compared with reported net income of $49.9 million, or $1.43 per share in 2007. Safe Harbor Statement
Certain statements in this news release constitute "forward-looking statements" within the pain meds meaning of the Private Securities Litigation Reform Act of 1995. "Given the challenging environment of 2008, we are pleased with the operating results over the last two quarters," stated Antons G.
For and other dr oz zoloft company information, visit. For the fourth quarter ended , Par reported total revenues of $161.3 million and a loss from continuing operations of $30.5 million, or $0.91 per share. "This momentum should continue into 2009 as the results of our restructuring takes pain treatment hold and solid product sales continue."
In October, Par announced its plans to resize its generic division by significantly reducing its research and development expense and trimming its product portfolio resulting in a workforce reduction of approximately 190. Fourth quarter 2008 reported, or GAAP, loss from continuing operations prescription medication also included the write-off of a restructuring charge of $15.4 million and other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal fees, $5.3 million gain on non-core ANDA sales and the sale of other product rights, $4.9 million impairment arthritis medicine charge related to various investments, and a $7.9 million gain related to shea debt extinguishment. Par anticipates these actions will generate annualized operating expense savings champix reviews in a range near $45 million.
For a copy of Par's 2008 Annual Report on Form 10-K, visit Investors/SEC Filings on the Par web site at. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended , in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Strativa's gross margin increased to 77.7% of branded revenues from 76.0% in 2007 due to revenue growth discussed above. By comparison, and in addition to the fourth quarter 2007 events cited above, reported GAAP income from continuing operations for the full year 2007 included a $20.0 million gain on the sale to Optimer of marketing rights to the investigational drug Difimicin (Par 101), a $4.5 million investment gain on the sale of shares of Optimer com stock, and net settlement gains of $0.6 million. Adjusting for these items and other special items, income from continuing operations for the fourth quarter 2008 would have been $7.1 million, or $0.21 per diluted cialis price 5mg share. Par's 2008 gross margin represented 30.5% of total revenues, a decrease from 34.9% in 2007. Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results
WOODCLIFF LAKE, N.J., / - / -- Par Pharmaceutical Companies, Inc.
By comparison, fourth quarter 2007 results included a pre-tax gain of $3.1 million from Par's sale of its remaining investment in Optimer Pharmaceutical, Inc. For the year ended total revenue decreased 24.9% to $578 million compared with the same period a year earlier as a result laser hair removal pittsburgh of a decrease in the number of new product launches, trimming of Par's generic product portfolio, increased competition in Par's generic products. Selling, General and Administrative
Selling, general and administrative (SGA) expense of $137.9 million for the year ended decreased slightly from $138.2 million in 2007. This is compared with reported revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, for the same period in 2007. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to diazepam online pharmacy any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.
As of , Par had working capital of $193.8 million, which includes $142 million of current liabilities due to mature in September 2010. For the full year 2008, Par reported a loss of $47.8 million, or $1.43 per share. Strativa revenues increased sildenafil ciprofloxacin levofloxacin viagra 2.7% from the prior year to $87.1 million driven by a mid-year price increase, fees related to the co-promotion of Androgel(R), and timing of trade buying patterns offset by a more challenging reimbursement environment. These benefits were tempered by $19.2 million of costs related to business development activities in support of Strativa Pharmaceuticals, Par's branded division, a $6.0 million loss on an investment, $1.6 million of severance costs. Revenues from Strativa represented 15.1% of total revenues, as compared to 11.0% in 2007.
For the year ended , Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share. The replay dial-in number is 888-286-8010 for domestic callers and 617-801-6888 for international callers. Par invites investors and the general public to listen to a webcast of the conference call. PRX) today reported fourth quarter and full year 2008 results ended. The decrease in SGA expense was primarily due to lower employee compensation, hauschka skin care the non-recurrence of the